Vladimir Benes1, Paul Collier1, Claus Kordes2, Jens Stolte3, Tobias Rausch1, Martina U Muckentaler4, Dieter Häussinger2, Mirco Castoldi2. 1. European Molecular Biology Laboratory, Genomics Core Facility, D 69117 Heidelberg, Germany. 2. Department of Gastroenterology, Hepatology and Infectious Diseases, Heinrich Heine University, D 40225 Düsseldorf, Germany. 3. RIKEN 1 230 0045, 1 Chome-7-22 Suehirochō, Tsurumi-ku, Yokohama-shi, Kanagawa-ken 230-0045, Japan. 4. 1] Department of Pediatric Oncology, Hematology and Immunology University of Heidelberg, D 69120 Heidelberg, Germany [2] Molecular Medicine Partnership Unit, University of Heidelberg, D 69120 Heidelberg, Germany.
Abstract
microRNAs are an abundant class of small non-coding RNAs that control gene expression post-transcriptionally. Importantly, microRNA activity participates in the regulation of cellular processes and is a potentially valuable source of biomarkers in the diagnosis and prognosis of human diseases. Here we introduce miQPCR, an innovative method to quantify microRNAs expression by using Real-Time PCR. miQPCR exploits T4 RNA ligase activities to extend uniformly microRNAs' 3'-ends by addition of a linker-adapter. The adapter is then used as 'anchor' to prime cDNA synthesis and throughout qPCR to amplify specifically target amplicons. miQPCR is an open, adaptable and cost-effective procedure, which offers the following advantages; i) universal elongation and reverse transcription of all microRNAs; ii) Tm-adjustment of microRNA-specific primers; iii) high sensitivity and specificity in discriminating among closely related sequences and; iv) suitable for the analysis of cellular and cell-free circulating microRNAs. Analysis of cellular and cell-free circulating microRNAs secreted by rat primary hepatocytes stimulated with cytokines and growth factors identifies for the first time a widespread modulation of both microRNAs expression and secretion. Altogether, our findings suggest that the pleiotropic activity of humoral factors on microRNAs may extensively affect liver function in response to injury and regeneration.
microRNAs are an abundant class of small non-coding RNAs that control gene expression post-transcriptionally. Importantly, microRNA activity participates in the regulation of cellular processes and is a potentially valuable source of biomarkers in the diagnosis and prognosis of human diseases. Here we introduce miQPCR, an innovative method to quantify microRNAs expression by using Real-Time PCR. miQPCR exploits T4 RNA ligase activities to extend uniformly microRNAs' 3'-ends by addition of a linker-adapter. The adapter is then used as 'anchor' to prime cDNA synthesis and throughout qPCR to amplify specifically target amplicons. miQPCR is an open, adaptable and cost-effective procedure, which offers the following advantages; i) universal elongation and reverse transcription of all microRNAs; ii) Tm-adjustment of microRNA-specific primers; iii) high sensitivity and specificity in discriminating among closely related sequences and; iv) suitable for the analysis of cellular and cell-free circulating microRNAs. Analysis of cellular and cell-free circulating microRNAs secreted by rat primary hepatocytes stimulated with cytokines and growth factors identifies for the first time a widespread modulation of both microRNAs expression and secretion. Altogether, our findings suggest that the pleiotropic activity of humoral factors on microRNAs may extensively affect liver function in response to injury and regeneration.
microRNAs (miRNAs) are short, non-coding RNAs (ncRNAs) that control gene expression at the
post-transcriptional level1. miRNAs are transcribed within long primary transcripts
that are processed via two successive RNase III-like enzyme mediated-cleavage steps. Drosha conduces
the first processing step in the nucleus by cleaving the primary transcripts to produce a
double-stranded precursor (2; 80–100 nts long). The second processing step
occurs in the cytoplasm where Dicer generates a short duplex RNA, consisting of a guide and
passenger strands (3; 19–24 nts long). Although either strand of the duplex
may act as a functional miRNA, the carrier strand is preferentially incorporated into the
RNA-induced silencing complex (4; RISC) where, in a sequence specific fashion,
interacts with the 3′-untranslated regions of target mRNAs either impairing mRNA translation
or stability5. Recent studies demonstrated the intimate connection between miRNA
expression and regulation of development67, differentiation89 and
metabolism1011. Furthermore, considering that aberrant miRNA expression has been
linked to the pathogenesis of human diseases121314, changes in the expression of
specific miRNAs may potentially provide valuable diagnostic and prognostic information15. In addition to cellular miRNAs, cell-free circulating miRNAs have been isolated in body
fluids16 and detected in tissue culture medium17. To date, two
different populations of cell-free circulating miRNAs have been identified; one included in exosomes
and one associated to the Argonaute proteins18. To date no function has been found
for the Argonate-associate miRNAs. However, exosomal-miRNAs are heavily investigated as potential
source of disease-associated biomarkers. Exosomes, are nano-sized (30–200 nm)
transporters involved in cell-to-cell communication through the shuttling of proteins, RNAs, and
lipids between cells19. The existence of a specific population of exosomal-associated
miRNAs circulating in the blood of healthy as well as diseased individuals have raised the
possibility that analysis of these miRNAs may identify clinically relevant biomarkers for the early
detection and in the monitoring of human diseases20.As miRNAs are isolated from heterogeneous sources with different methodologies, it is important
to have reliable, reproducible and robust tools for the quantification of miRNA expression by using
qPCR. Importantly, the method of choice should convey the different experimental set-ups used to
isolate miRNAs (i.e. cellular vs exosomal) into a unique down-stream application. To date various
commercial methods dedicated to miRNA detection by qPCR are available. However, commercial platforms
are not particularly flexible to user needs, nor readily adaptable to the increasing numbers of
known miRNAs. Additionally, commercial platforms frequently only provide miRNA-specific primers
covering primarily human, mouse and rat as model organisms. Therefore, researchers working with
‘non-canonical’ animal models or seeking to validate newly discovered miRNAs do not
have ready access to this technique. In order to overcome these limitations, we have developed an
‘open source’ miRNA specific qPCR platform named ‘miQPCR’. The
miQPCR approach is based on well-established techniques as it exploits the activity of truncated T4
RNA ligase 2 (Rnl2tr) to join the 5′-end of a linker adaptor to the 3′-end of
single-stranded RNAs (2122; ssRNAs) including miRNAs. Standard approaches are used
to reverse transcribe linker-tagged miRNAs and a fraction of the synthesized cDNA is amplified and
quantified in a qPCR assay.Several published studies indicate that miRNAs and cytokine activities are strongly
interconnected, as it was shown that miRNAs expression is modulated in response to cytokine
stimulation23, while cytokine expression is regulated by miRNAs2425.
As miRNAs are pivotal in the modulation of liver function26, it is expected that
cytokines or growth factors will modulate function of hepatic miRNAs during inflammation or liver
injury and regeneration. However, to the best of our knowledge the modulation of miRNA activity by
cytokines or growth factors in the liver has not been systematically investigated. In this study we
employed miQPCR to analyze the activity of growth factors [Fibroblast Growth Factor 2 (basic); FGF2,
Fibroblast Growth Factor 4; FGF4 and Hepatocyte growth factor; HGF] and cytokines (Interleukin-1
alpha; IL-1α, Interleukin-6; IL-6, Interferon-beta; INF-β, and Transforming Growth
Factor-beta1; TGF-β1) on both, the expression and secretion of a panel of selected miRNAs in
cultured rat primary hepatocytes. To the best of our knowledge, this is the first study showing that
cytokines and growth factors are able to modulate both the expression and the secretion of miRNAs in
cultured primary hepatocytes. Importantly, we identified that FGF2, FGF4 and INF-β,
down-regulated the expression of several miRNAs in the cultured hepatocytes, while IL-6,
INF-β and TGF-β1 are able to modulate the quantity of exosomal-miRNAs secreted by
the primary hepatocytes into the culture medium. Altogether, our data indicate that the pleiotropic
effect of cytokines and growth factors on miRNAs expression and secretion might have an extensive
effect on liver function whilst the liver is recovering from different insults or during chronic and
acute liver diseases.
Results
miQPCR workflow, miRNA elongation and reverse transcription
miRNA expression profiling is challenging as mature miRNAs are; i) short single stranded RNAs
(22–24 nts); ii) their CG content varies between 33% of hsa-miR-144 and 89% of
hsa-miR-4665-3p resulting in a wide range of Tms; iii) miRNAs only represent a small fraction
of the cellular RNA; iv) miRNA target sequence is contained in its precursors (i.e. pri- and
pre-miRNAs); and v) miRNAs are redundant and exist in families where individual members can differ
by just a single nucleotide27. To overcome these limitations, we have developed an
innovative approach for cDNA synthesis, where miRNAs’ 3′-ends are universally
elongated via the ligation of a 26 nts long oligonucleotide adaptor (named miLINKER). Thereafter,
the reverse transcription of elongated miRNAs is primed by the annealing to an optimized reverse
transcription primer (named mQ-RT). An important characteristic of the presented method is that the
miLINKER does not contain the full sequence for the universal qPCR primer (named Upm2A), as the
missing portion of the sequence is introduced in the amplicon during the reverse transcription via
the mQ-RT primer. Reasons for this include an increased specificity of the qPCR assay as well as in
the possibility of modifying or adapting the universal qPCR primer without the need of changing the
miLINKER sequence. The complete procedure, which requires 10 ng of total RNA, is generally
carried out in 75 minutes and up to 100 individual qPCR assays can be carried out from a
single cDNA (Fig. 1a; see Table 1 and on-line Material
and Methods for step-by-step miQPCR protocol, optimized qPCR master mix calculator and qPCR cycler
program).
Figure 1
Workflow of cDNA synthesis following the miQPCR approach.
a) During the first step the 3′-end of ssRNA is enzymatically ligated to the
5′ end of miLINKER by truncated T4 RNA ligase (time ~30 min). In the second
step, a reverse transcriptase is used to reverse transcribe elongate miRNAs into cDNA with a
universal reverse-transcription primer (mQ-RT, time ~45 min). In the third and final
step, cDNA is diluted, the miRNA of interest is amplified by qPCR using a reverse universal primer
(Upm2A) and a forward miRNA-specific primer while the amplicon is detected by using SYBR Green I.
b) Multiple alignment among the complement reverse of the linker adaptor (miLINKER) and the
sequences of the reverse transcription primer (mQ-RT) and of the universal qPCR primer (Upm2A). All
the sequences are indicated in the 5′ → 3′ orientation. For miLINKER, mQ-RT
and Upm2A sequences see Supplementary Table 1a and
1b.
Table 1
Composition of the different master mixes required to carry out cDNA synthesis and qPCR
analysis by using miQPCR.
miQPCR master mixes calculations (INCLUDING 10% extra
volume in calculations):
Volume (μl)
X Samples
Check
a) Elongation Mix
10X T4 Rnl2 Buffer (NEB)
0.90
□
150 mM MgCl2 (final 5 μM)
0.30
□
50% PEG 8000 (final 15%)
2.70
□
miLINKER (5 mM)
0.30
□
RNase Inhibitor (40 U/μl)
0.10
□
Rnl2tr K227Q (NEB)
0.20
□
b) cDNA Mix1
dNTPS (10 mM)
0.50
□
ddH2O (Nuclease Free)
7.0
□
mQ-RT primer (10 mM)
0.25
□
c) cDNA Mix2
5X RT Buffer (Takara)
4.40
□
PrimeScript (Takara)
0.25
□
ddH2O (Nuclease Free)
0.85
□
qPCR master mix calculation (extra volume NOT included in calculation):
d) qPCR Master Mix
ddH2O (Nuclease Free)
7.4
□
Upm2A primer (10 mM)
0.30
□
miRNA primer (10 mM)
0.30
□
2X SYBR Green I mix
10.0
□
miLINKER design
To elongate miRNAs uniformly and to perform cDNA synthesis, miQPCR relies on the ligation of an
adenylated linker adaptor (the miLINKER), to miRNA 3′-ends28. Significantly,
as this reaction is conducted in absence of ATP the formation of circularized RNAs as a ligation
byproduct is greatly reduced22. The miLINKER is a 26 nts long DNA oligo where the
5′-end present a 5′, 5′-adenyl group, while a Dideoxycytidine (ddC) blocks
the 3′-end of the miLINKER. Notably, the miLINKER sequence was derived from the Solanum
tuberosum (potato) phyB gene (29; PHYB). PHYB gene, which is species-specific,
encodes for a photoreceptor involved in the development of purple coloration in potato root. Due to
its unique features, PHYB has been previously used for developing the ‘SPUD assay’,
which was created to assess the presence of polymerase inhibitors in qPCR assays30.
Design and optimization of miRNA-specific primers
The specificity and sensitivity of qPCR assays rely on primer design. For the intrinsic nature of
the mature miRNAs, the design of miRNA-specific primers is particularly challenging. miRNAs have
highly heterogeneous GC content resulting in a wide range of predicted Tm. As qPCR assays are
run at 60 °C, differences in annealing temperatures are likely to impair either the
specificity (predicted Tm > 62 °C) or sensitivity
(predicted Tm < 55 °C) of a number of miRNA assays. To
evaluate the Tm distribution across the miRNAs encoded in mammalian genomes, Tm
prediction for all the human- and mouse-miRNAs included in the miRBase [version 19;27] was carried out (Fig. 2). This approach indicates that ~40% of the
human and mouse miRNAs had predicted Tms within what we consider the optimal qPCR range (i.e.
between 55 °C and 62 °C). Whereas the remnant miRNAs predicted
Tms were either above (~40% miRNAs
Tm > 62 °C) or below (~20% miRNAs
Tm < 55 °C) the optimal qPCR range (Fig.
2a,b). A major advantage of the miQPCR method is that following elongation and reverse
transcription the length of the target amplicon is around 60 nts instead of 22–24 nts.
Hence, the sequence of miRNA-specific primers can be adjusted to achieve a consistent Tm
across different assays. This is (empirically) achieved through either the shortening of the
5′-ends of primers with a predicted Tm higher than 62 °C or
elongating the 3′-ends of primers with a predicted Tm lower the 55 °C
into the miLINKER’s 5′-end. As a proof of principle, this empirical method was
applied in the design of gene specific primers targeting all human and mouse miRNAs contained in the
miRBase (version 19; Fig. 2c,d). Tm prediction carried out on human and
mouse optimized primers shows that the Tms of ~96% of miQPCR-designed primers falls
within the desired Tm range (see on-line Material and Methods for the stepwise optimization
of miRNA primer design. The sequences of Tm adjusted primers of all miRNAs contained in
miRBase version 19 are available in the Supplementary Table
2).
Figure 2
Tm prediction of human and mouse miRNAs contained in the miRBase v19.
Analysis of the melting temperature (Tm) indicate that around 40% of the human a)
and 37% of the mouse b) sequences show a predicted Tm within the optimal range for
qPCR amplification
(55 °C < Tm < 62 °C).
More than 43% of the sequences (for both human and mouse) show a predicted Tm above the
optimal range (Tm > 62 °C) while less than 20% displayed a
predicted Tm below the optimal range (Tm < 55 °C).
By implementing miQPCR primer design (For complete prediction see Supplementary Table 2) we were able to adjust the predicted Tm
for most of the primers (~97%, c human and d mouse) to fall within the optimal
conditions for qPCR assays
(55 °C < Tm < 62 °C).
Specificity and sensitivity assessment of miQPCR assays
To assess miQPCR specificity in discriminating between closely related sequences we focused on
the analysis of the Let-7 family. The analysis of these miRNAs poses several challenges, as members
of this family are nearly identical (Fig. 3a). To test specificity, separate
assays were designed to monitor the cross reactivity of six related members of the Let-7 family
(Let-7a, Let-7b, Let-7c, Let-7d, Let-7e and Let-7f). As shown in Fig. 3b every
assay tested exhibited substantial target sequence specificity. Importantly cross talk between
primers designed to amplify specifically a member of the family and other members of the Let-7
family was marginal and with limited overlap. Overall, these data indicate that miQPCR assay is able
to discriminate among closely related sequences.
Figure 3
miQPCR assay discriminates among the closely related members of the Let-7 family.
a) Multiple alignment of the six selected members of the Let-7 family. b) Six
members of the Let-7 family (Let-7a, Let-7b, Let-7c, Let-7d, Let-7e and Let-7f) were individually
spiked into yeast total RNA. Following, 10 ng of yeast total RNA containing
2*108 copies of the selected miRNA (or 3.3 fmol) were reverse transcribed
according to the miQPCR protocol and 100 pg of yeast RNA (containing 2*106
copies of each individual miRNA) were analyzed for cross reactivity. Values in the panel B represent
the relative detection (expressed in percentage) calculated based on Ct difference between the
perfectly matched and mismatched targets. Data were calculated from six independent cDNAs
synthesis.
To the best of our knowledge, the truncated T4 RNA used in the miQPCR protocol (i.e. Rnl2tr) will
elongate all the RNAs presenting an accessible single stranded 3′ end, including many
miRNA-precursors. However, the primer design is what ensures the discrimination between the mature
and precursor miRNAs. As proof of principle, miRNA-specific primers targeting miR-122-5p, miR-122-3p
and miR-21-5p were designed following the standard miQPCR design and without the additional
3′ end ‘G’ (for sequences see Supplementary Table 1a). Importantly, standard miQPCR primers generates a single specific
melting curve (Fig. 4a), while the ‘G-less’ primers generated
melting curves with two distinct peaks (Fig. 4a). Overall, these data show
that the miQPCR assay enables the design of miRNA specific primers discriminating between mature
miRNAs and their precursors.
Figure 4
Discrimination between mature miRNAs and their precursors.
To identify whether miQPCR primer design is able to discriminate between mature miRNAs and their
precursors miRNA-specific primers targeting miR-122-5p, miR-122-3p and miR-21-5p were designed
according to the standard miQPCR design protocol (i.e. containing a 3′ end
‘G’ overlapping with the miLINKER) or without miLINKER overlap. a) The
primers designed with miLINKER overlap produces single pick melting curves, while b) the
amplification products generated by the ‘G-less’ primers have melting curves with
double picks. Melting curves from six biological replicas are shown. Negative RT and NTC did not
show any amplification.
The dynamic range and sensitivity of the miQPCR assays were evaluated using synthetic Let-7a and
Let-7e (Fig. 5). Copy numbers of synthetic miRNAs were calculated based on
their concentration and cDNAs were diluted over six orders of magnitude (Fig.
5a,b). The miQPCR assays displayed linearity between the input copy number of target and Ct
value, and it is capable of detecting as little as twenty copies in the PCR assay. To further
evaluate miQPCR dynamic range extensively, four additional miRNA assays (miR-122, miR-192, miR-21
and miR-16) were analyzed in cDNA synthesized from mouse liver RNA (Fig. 5c
and in Supplementary Figure 5). Analysis of standard
curves shows that endogenous miRNAs are detected over several orders of magnitude, while abundant
miRNAs such as the liver specific miR-12231 are detected from as little as
6 fg of cDNA. To summarize, the presented data demonstrate that the cDNA synthesis following
the miQPCR protocol enables for the design of highly sensitive and specific primers, which
efficiently discriminate between closely related sequences.
Figure 5
miQPCR approach displays a wide dynamic range and high sensitivity.
Top and middle panels; Two members of the Let-7 family (Let-7a and Let-7e) were spiked into yeast
total RNA and 10 ng of yeast total RNA containing 2*108 copies of the
selected miRNA (or 3.3 fmol) were reversed transcribed using the miQPCR. Following cDNA
synthesis 100 pg of yeast RNA (containing 2*106 copies) were used to create
five 1:10 linear dilution, which were analyzed by qPCR. Data are represented as
average ± standard deviation calculated from six independent cDNAs
synthesis. Analysis indicates that miQPCR can detect as little as 20 copy of the target miRNAs and
that the detection of the analyzed targets sequence is linear (as shown by the linear regression
R2). Lower panel; To evaluate the performance of the miQPCR in a physiological
context, liver total RNA was reverse transcribed and 100 pg of cDNA were used to prepare 1:5
scalar dilutions (100 pg, 20 pg, 4 pg, 800 fg, 160 fg,
32 fg and 6 fg). Next, the expression of four endogenous miRNAs (miR-122, miR-192,
miR-21 and miR-16) was analyzed by qPCR, showing that the detection of the analyzed targets sequence
is linear (as shown by the linear regression R2). For highly abundant RNA targets
(i.e. miR-122), the detection by qPCR maintains its linearity also when the input material is
greatly diluted. Data are represented as Ct average ± standard deviation
calculated from four independent cDNAs synthesis.
miQPCR comparison with established microRNA profiling technologies
To assess whether miQPCR delivers data comparable to commercial miRNA-qPCR platforms, we
benchmarked miQPCR against the ‘gold-standard’ for quantification of miRNA
expression by qPCR, the TaqMan miRNA assays32. For this purpose, FirstChoice total
RNAs (Life Technologies) isolated from either mouse liver or heart were labeled and hybridized to
the miCHIP microarray platform as previously described33. Microarray analysis
identified a panel of miRNAs, which are either highly expressed in the heart (miR-1, miR-133a and
miR-16) or in the liver (miR-122, miR-192 and miR-194) or invariant (miR-21; Supplementary Figure 1a). The expression of the selected miRNAs and
RNU6 was measured by using either TaqMan or miQPCR approaches (Fig. 6 and Supplementary Figure 1b). The data show a perfect overlap
between the two qPCR platforms, showing that the miRNA profiling by using miQPCR (Fig. 6, higher panel) and TaqMan (Fig. 6, lower panel) accurately
reflect the miRNA expression patterns in the mouse liver and heart as measured by microarrays.
Importantly, cDNA synthesis and analysis by miQPCR compared to the TaqMan approach required less
material (i.e. less RNA), reduced workload (i.e. less pipetting) and considerably reduced the costs
per qPCR assay.
Figure 6
Cross platform comparison of miRNA expression between TaqMan and miQPCR miRNA assays.
Total RNA from heart or liver were reverse transcribed according to the miQPCR and TaqMan
protocols and the expression of 7 miRNAs (miR-1, miR-133b, miR-16, miR-122, miR-194 and miR-21) and
a small nuclear RNA (RNU6) was measured by qPCR with respectively SYBR-Green (top panel) or TaqMan
probes (lower panel). Data shows a nearly perfect correlation between the TaqMan and the miQPCR
platform. For each assay, Cts from four independent cDNAs synthesis were averaged and the
ΔΔCt of heart vs liver were calculated. For actual Cts values (represented as
average ± standard deviation) and for the comparison with microarray data
see Supplementary Figure 1.
Cytokines and growth factors modulate both the expression and the secretion of miRNA in
cultured rat primary hepatocytes
In order to evaluate the effects of cytokines and growth factors on miRNA expression and
exosomal-secretion in the liver, rat primary hepatocytes were stimulated for 24 hours with
either FGF2, FGF4, HGF, IL-1α, IL-6, INF-β or TGF-β1. At the end of the
treatment, cells and conditioned medium were collected and isolation of both total and exosomal RNAs
were carried out as described. Following RNA quality control and cDNA synthesis, the expression of a
panel of miRNAs was analyzed by qPCR (Fig. 7). Importantly, miRNAs included in
this panel were selected with respect to their expression in the liver (miR-12231,
miR-19431 and miR-19231), their function during infection and
inflammation (miR-1553435 and miR-1503637), their pro-fibrotic
activity (miR-142-3p38), or their altered expression during fibrosis or
hepato-cellular carcinoma (miR-30d39, miR-9840, miR-92a41, miR-2142, miR-18a43 and miR-2234244). Analysis of
cellular miRNAs identified that administration of FGF2, FGF4 or INF-β significantly
regulated the expression of several miRNAs (Fig. 7a) including the
liver-enriched miR-19431. miR-194 expression is regulated by hepatocyte nuclear
factor 1α (HNF1-α45) and its down-regulation may have an effect on
cellular mobility46. Additionally, our data indicate that administration of FGF4
along with IL-1α and INF-β significantly down-regulates miR-21, which regulates cell
cycle progression during mouse liver regeneration47. Overall, we observed that the
expression of cellular miRNAs shows a trend toward the down-regulation, suggesting that the activity
of extracellular signals on hepatocytes may decouple miRNA-mediated translational repression. On the
other hand, levels of exosomal-miRNAs were mostly up-regulated by the treatments (Fig. 7b). Moreover, it can be observed that exosomal-miRNAs preferentially respond to
cytokines administration, in contrast to cellular miRNAs that preferentially respond to growth
factors. Specifically, IL-6 and TGF-β1 regulated the expression of 53% (6 out of the 11) and
63% (7 out of the 11) of the exosome-secreted miRNAs respectively. Changes in levels of
exosomal-miR-98 were not analyzed since miR-98 was not detectable in exosomes secreted by control
primary hepatocytes (data not shown). Overall, this data suggests a complex interplay between the
signaling pathways down-stream to cytokines and growth factors in the modulation of miRNAs
expression and exosomal-secretion, interaction that will be further investigate in future
studies.
Figure 7
Modulation of miRNA expression and secretion in rat primary hepatocytes stimulated with
cytokines and growth factors.
Rat primary hepatocytes were stimulated with growth factors (FGF2, FGF4 and HGF) or cytokines
(IL-1α, IL-6, INF-β and TGF-β1) for 24 hours. Expression profiling
of a selected panel of miRNAs was analyzed by using miQPCR in either cellular a) or exosomal
b) RNAs. Statistical analysis was performed by unpaired T-test of control group
(n = 12) versus individual treatment groups (n = 12) for each
miRNA.
The presented data indicate that miQPCR greatly simplified the analysis of these experiments by
significantly reducing the sample handling. For this study, four independent experiments were
performed, where each independent experiment included triplicates for the eight different
conditions. For each experiment 24 cellular and 24 exosomal RNAs were investigate, requiring the
synthesis of 192 individual cDNAs to complete the whole analysis. If we had measured the expression
of 12 different miRNAs using similar analysis performed with TaqMan miRNA-assays, which requires
individual cDNAs to be synthesized through miRNA-specific stem-loop reverse transcription
primers32, we would have required the synthesis of 2304 individual cDNAs.
Discussion
In little more than a decade miRNAs have deeply affected every field of biology and medicine and
their discovery has effectively modified the way we view and approach the regulation of gene
expression as well as open up new possibility in the search of clinically relevant biomarkers15. Herewith, we described ‘miQPCR’ an innovative approach for the accurate
and sensitive quantification of miRNAs by using qPCR. With the miQPCR method, we established a
method for achieving the universal reverse transcription of all the miRNAs contained in the RNA
sample. Essential components of this system are: i) the miLINKER, an oligonucleotide adapter
encompassing the sequence required for ligation and reverse transcription; ii) the Rnl2tr, which
joins the 5′-end of the miLINKER with the 3′-end of miRNAs; iii) the mQ-RT primer
that reverse transcribes and extends the ligated miRNAs to their final size; and iv) the Tm
adjusted miRNA specific primers. Importantly, T4 RNA ligases are a powerful class of enzymes
enabling the application of several methods including miRNA cloning4849, miRNA
labeling for microarray33, miRNA labeling for liquid phase detection assays50, cDNA synthesis28 and in the generation of small RNA library for next
generation sequencing51.Although the miQPCR method has not been published before, we have previously shown that the
miQPCR is a suitable technique for measuring miRNA level in RNAs extracted from tissues, primary
cells and cell lines52, from serum53, as well as from RNA extracted
from Formalin–fixed and paraffin–embedded (FFPE) specimens (11; and
Supplementary Figure 2). Notably, beside miQPCR no other
approaches enable the ‘universal’ or ‘multiplexed’ elongation and
reverse transcription of miRNAs. In the first approach, E. coli Poly (A) Polymerase (PAP) is
used to add, in a template independent fashion, adenosine nucleotides to the 3′-end of all
the RNA contained in the sample. While in the latter approach TaqMan Low density miRNA Array card
(TLDA, Applied Biosystem) enables the parallel screening of large number of miRNAs by using qPCR
(PAP and TLDA have been reviewed in54). Drawback of these methods compared to miQPCR
is that [unless Locked Nucleic Acid (LNA) are used] the PAP does not allow the design of
miRNA-specific primers discriminating between mature and miRNA precursors, whereas TLDAs consist of
custom-made 384-well micro fluidic cards, which are not flexible in their design. Furthermore, TLDAs
requires the acquisition of dedicate equipment that will considerably increase the price for
reaction.The recent discovery of cell-free miRNAs circulating in the blood of healthy as well as diseased
individuals1617, have raised the possibility that significant changes in the levels
of specific miRNAs may reflect the clinical manifestation of the disease20. Hence, to
demonstrate the ability of miQPCR to expression profile miRNAs in both cellular and
exosomal-isolated RNAs, we used miQPCR to measure the expression levels of cellular and
exosomal-miRNAs in rat primary hepatocytes stimulated with a panel of cytokines and growth factors.
Interestingly, we discovered that both cytokines and growth factors were able to affect the
expression or the secretion of cellular or exosomal-miRNAs (Fig. 7a,b). Our
data clearly show that expression of miRNAs in hepatocytes tends to be down-regulated by the
treatments. Of note, miR-21, a well-characterized oncomiR regulating cell cycle progression47, is significantly down-regulated by FGF4, IL-1α and INF-β
administration, suggesting a potential tumor-suppressor or anti-proliferative activity of these
factors on hepatocytes. On the other hand, we observed that IL-6 and TGF-β1 administration
up-regulated between 50 and 60% of the analyzed exosomal-miRNAs, suggesting a pleiotropic activity
of these cytokines on the composition or secretion of exosomal-miRNAs. Importantly, we noticed that
the up-regulation of a specific miRNAs in the exosomes is not associated with its down-regulation at
cellular level, suggesting that cellular and exosomal-miRNAs are regulated via different signaling
pathways. Future experiments will focus on the analysis and characterization of molecular pathways
down- and up-stream to the regulated cellular miRNAs, as well as in assessing the functionality of
exosomal-associated miRNAs in respect of inter-cellular communication.In summary, we have created an innovative, simple, flexible, robust and inexpensive tool for
monitoring the expression profile of miRNAs by using qPCR. The advantages of the miQPCR protocol
over existing miRNA-qPCR platform are: i) a ‘one-step’ reverse transcription of all
RNAs contained in the sample; ii) Tm adjustment of miRNA-specific primers; iii) simple and
flexible primer design and; iv) an open and cost effective platform, which achieve optimal
performance of the qPCR assay. Based on the presented data we expect that miQPCR can greatly
facilitate miRNA expression profiling in biological and clinical samples.
Methods
miLINKER and mQ-RT design
The miQPCR method consists in two distinct steps, the RNA elongation and reverse transcription.
RNA elongation is achieved through the ligation of the miLINKER (a 26 nts long linker-adaptor; IDT
USA; Supplementary Table 1) to RNAs 3′-ends. For
increased specificity, the miLINKER sequence was derived from the tuberosumphyB gene (GeneBank
Y14572) which has been optimized not to hybridize with any known sequences in published genomes.
miLINKER is designed to be a substrate of the truncated T4 RNA ligase 2 K227Q (Rnl2tr, NEB Cat:
M0242L). For this purpose, the linker was synthesized with a 5′, 5′-adenyl group at
the 5′-end, while a Dideoxycytidine group blocks the linker’s 3′-end (Fig. 1a and Supplementary Table 1a). The
miLINKER ligation to mature miRNAs (22–24 nts) results in the formation of a molecule 48 to
50 nts long. The reverse transcription via an optimized reverse transcription primer named mQ-RT,
which brings the final size of the amplicon to 59 to 61 nts that is the optimal amplicon range for
qPCR. qPCR assays are run with a miRNA specific primer and a universal reverse primer named Upm2A
(Fig. 1b).
Rat primary hepatocyte preparation, cytokine stimulation and RNA isolation
All experiments and experimental protocols involving animals were approved by and conducted in
accordance with the guidelines of the University of Düsseldorf Institutional Animal Care and
Use Committee. Primary hepatocytes were isolated from male Wistar rats (150–200 gr)
essentially as described55. In brief, hepatocytes were isolated after serial
perfusion of rat liver by Hanks’s balanced salt solution (HBSS, Sigma Cat: H6648) and
collagenase CLS type II solution (50 mg/150 ml, Biochrom Cat: C2-22). The
collagenase was dissolved in HBSS (Sigma Cat: H8264) supplemented with albumin fraction V
(3 gr/150 ml, Roth Cat: CP84.1) and applied by circulated perfusion for
17–20 minutes at 37 °C. After sufficient digestion, a pair of
tweezers was used to disrupt the liver tissue and the resulting cell suspension was centrifuged
three times at 44 × g for 3 minutes to remove non-parenchymal cells.
The hepatocyte pellet was suspended in culture medium (DMEM-F12, Gibco Cat: 11320-074) supplemented
with 10% (v/v) fetal calf serum (FCS, Biochrom Cat: S0615) and 1% (v/v)
penicillin-streptomycin-amphotericin B solution (Gibco Cat: 15240-062). About 6.6*105
hepatocytes per well were plated out using 6-well plates (Greiner Cat: 657169). The plastic surface
of the 6-well plates was pre-coated by collagen type I (Sigma Cat: C3867,
6–10 μg/cm2). The adherent hepatocytes received new medium
after 3 hours of culture at 37 °C and 5% CO2. Primary hepatocytes
were allowed to recover for 24 hours and the medium was then switched to a serum-free medium
comprising of DMEM-F12 (Gibco), 1% (v/v) penicillin-streptomycin-amphotericin B solution (Gibco) and
1% (v/v) linoleic acid/bovine serum albumin solution (Sigma Cat: L9530) for additional
24 hours. Subsequently, primary hepatocytes were stimulated with 1.5 ml of
serum-free medium containing either cytokines or growth factors [TGF-β1 (10 ng/ml;
Sigma Cat: T5050), IL-6 (50 ng/ml; Sigma Cat: I0406), IL-1α (25 ng/ml; Sigma
Cat: I3901), INF-β (1000 U; Millipore Cat: IF011), HGF (20 ng/ml; PreproTech
Cat: 100-39), FGF2 (100 ng/ml; Sigma Cat: F0291) and FGF4 (100 ng/ml; PreproTech
Cat: 100-31)], or cultured in 1.5 ml serum free medium (control) for 24 hours.
Isolation, purification of cellular and exosomal RNAs
Following treatment of primary hepatocytes with cytokines and growth factors, conditioned mediums
were collected and stored frozen while cell were rinsed in cold PBS, scrapped from the wells and
lysate in 500 μl of Qiazol. Cellular RNAs were isolated with the miRNeasy mini kit
(Qiagen Cat: 217004) by following manufacturer instructions and eluted in 50 μl of
nuclease free water. To isolate exosomal-miRNAs, conditioned mediums were thaw and pass through
0.45 μm filter syringe. Following, 500 μl of Total Exosome Isolation
Reagent (Invitrogen Cat: 4478359) were added to 1 ml of filtered medium and incubated ON at
4 °C. Following incubations, the samples were centrifuged at
10000 × g for 60 minutes at 4 °C and the resulting
exosomal pellets dissolved in 500 μl of Qiazol. Exosomal RNAs were isolated
according to the miRNeasy protocol and eluted in 50 μl of nuclease free water.
Concentrations and quality of cellular RNAs were estimated respectively by using NanoDrop ND-100
(Thermo Scientific) and non-denaturing agarose gel.
Genome wide analysis of miRNAs with miCHIP
MiRNA expression profiling was performed using the miCHIP microarray platform as described3356. In brief, 500 ng of FirstChoice liver or heart total RNA were labeled with
a Cy3–conjugated RNA linker (Biospring, Frankfurt, Germany) and hybridized on the
microarray. miCHIP is based on locked nucleic acid (LNA) technology, whereby LNA–modified
Tm–normalized miRCURY capture probes (Exiqon, Denmark) based on miRBase release 11 were
printed on Codelink slides (GE Healthcare, Munich, Germany). Microarray images were generated using
the Genepix 4200AL laser scanner (Molecular Devices, Biberach and der Riss, Germany) in batches
using the Genepix auto PMT (Photo Multiplayer). The ‘MultiExperiment Viewer’ MeV was
used to execute the statistical technique SAM (Significance Analysis of Microarrays) to identify
miRNAs of interest.
cDNA synthesis and qPCR analysis following the miQPCR and the TaqMan platforms
miQPCR assay
The presented method exploits the characteristic of Rnl2tr (NEB; Cat M0242L) and PrimeScript
(Takara; Cat 2680A) to respectively elongate and reverse transcriptase elongated miRNAs. To the
purpose of elongate miRNAs, 10 ng of total RNA (or 4 μl of miRNeasy isolated
Exosomal-RNAs) are dilute into 4 μl of nuclease free water, mixed with
4 μl of Elongation Mix (Table 1a) and incubated for
30 minutes at 25 °C. At the end of the incubation, samples are hold at
10 °C. Following, 7 μl of cDNA Mix1 (Table
1b) were added to the ligated RNAs and incubated at 85 °C for
2 minutes followed by cooling to 46 °C. In the last step,
5 μl of cDNA Mix2 (Table 1c) are then added to each
sample (Final volume 20 μl) and elongate miRNAs are reverse transcribed at
46 °C for 30 minutes followed by 5 minutes at 85 °C.
At the end of the reverse transcriptase inactivation samples are hold at 10 °C.
cDNAs are diluted to 50 pg/μl by the addition of 180 μl of
nuclease-free water (final volume 200 μl) and stored at
−20 °C until use. For qPCR assays, 2 μl of diluted cDNA
(equivalent to 100 pg) was mixed with primers, SYBR Green I (Life Technologies, Cat:
4367659) and nuclease free water (for the detailed qPCR master mix see Table
1d) and run on a 7500 Real-Time PCR instrument (Applied Biosystems). The 7500 cycler was
programmed as follow: 95 °C for 10 minutes, followed by 50 cycles of
95 °C for 10 seconds, 60 °C for 35 seconds,
including dissociation step (ramping from 60 °C to 95 °C) for
monitoring melting curve of the amplification products. Calculation for the optimal miLINKER (Supplementary Figure 3) and Poly Ethylene Glycol (PEG; Supplementary Figure 4) concentrations are included in the
Supplementary material and methods section.
TaqMan miRNA assay
cDNA for TaqMan assay were essentially prepared following the provider instructions. Briefly
10 ng of liver or heart total RNAs were reverse transcribed with individual stem-loop
RT-primers for miR-1 (Cat: 002222), miR-16 (Cat: 000391), miR-133a (Cat: 002246), miR-122 (Cat:
000445), miR-192 (Cat: 000491), miR-194 (Cat: 000493), miR-21 (Cat: 000397) and U6 (Cat: 001973).
Following reverse transcription, one (1) ng of each individually synthesized cDNA was used in the
qPCR assay with TaqMan probes.All the cDNAs syntheses were carried out in 200 ml PCR tubes in a PCR cycler (PCT-225
Thermal Cycler, MJ Researcher). Heart and liver total RNA used in comparison between the different
platforms were purchased from Life Technologies (FirstChoice mouse total RNA, Life Technologies Cat:
AM7816 and AM7810). Relative miRNAs expressions were determined by using the ΔΔCt
methods57 within qBase58 or manually in Microsoft Excel.
Synthetic miRNAs and miRNA standard curves
16.5 fmol (equivalent to 1*109 copies) of synthetic miRNAs (Let-7a,
Let-7b, Let-7c, Let-7d, Let-7e and Let-7f) were spiked into 50 ng of yeast RNA. cDNA was
synthesized from 10 ng of spiked RNAs (containing 2*108 copies) as described
above. cDNAs were diluted with nuclease free water and the equivalent of 100 pg of reverse
transcribed RNA (containing 2*106 copies) were amplified by using Upm2A and each of
the optimization primers designed to amplify the selected members of the Let-7 family (Supplementary Table 1c). Yeast total RNA was chosen to create a
complex environment as it was shown that yeast RNA does not contains miRNAs-like molecules59.For the determination of standard curves, 10 ng of liver total RNAs were reverse
transcribed following the miQPCR protocol. Following reverse transcription, nuclease free water was
used to bring the final volume of the cDNAs to 200 μl (or 50 pg/μl)
and seven 1:5 linear dilutions were prepared (Fig. 5). Following,
2 μl of each dilution was analyzed in qPCR assays by using Upm2A universal primers
and miR-122, miR-16, miR-192 or miR-21 as miRNA-specific primers (the sequences of the primers used
in this study are listed in the Supplementary Table 1b and
1c).
Prediction of duplex molecule Tms
Melting temperatures of individual sequences were calculated by using the freely available
“Tm calculator” tool (see below). The Tm of the complete miRBase v19
represented in Fig. 2 and included in Supplementary Table 2 were calculated by using Breslauer thermodynamic parameters60.
Statistical analysis and World Wide Web tools
To evaluate whether the observed differences between two groups were significant we employed the
unpaired T-test. Statistical analyses were calculated either with Microsoft Excel or by using
QuickCalcs t test calculator, GraphPad Software, Inc. Accessed 12 November 2014, (http://www.graphpad.com/quickcalcs/ttest1.cfm?Format=SD).Sequence of mature miRNA was downloaded from the miRBase database27: (http://www.mirbase.org/).The predicted Tms of the duplex molecule were calculated by using the web based Tm
calculator: (http://www.appliedbiosystems.com/support/techtools/calc/).Primers were analyzed for the presence of primer-dimer and secondary structure by using the web
based OligoAnalyzer from IDT: (http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/Default.aspx).
Additional Information
How to cite this article: Benes, V. et al. Identification of cytokine-induced
modulation of microRNA expression and secretion as measured by a novel microRNA specific qPCR assay.
Sci. Rep. 5, 11590; doi: 10.1038/srep11590 (2015).
Authors: Lori A Neely; Sonal Patel; Joanne Garver; Michael Gallo; Maria Hackett; Stephen McLaughlin; Mark Nadel; John Harris; Steve Gullans; Jenny Rooke Journal: Nat Methods Date: 2006-01 Impact factor: 28.547
Authors: Beiyan Zhou; Stephanie Wang; Christine Mayr; David P Bartel; Harvey F Lodish Journal: Proc Natl Acad Sci U S A Date: 2007-04-16 Impact factor: 11.205
Authors: Pablo Landgraf; Mirabela Rusu; Robert Sheridan; Alain Sewer; Nicola Iovino; Alexei Aravin; Sébastien Pfeffer; Amanda Rice; Alice O Kamphorst; Markus Landthaler; Carolina Lin; Nicholas D Socci; Leandro Hermida; Valerio Fulci; Sabina Chiaretti; Robin Foà; Julia Schliwka; Uta Fuchs; Astrid Novosel; Roman-Ulrich Müller; Bernhard Schermer; Ute Bissels; Jason Inman; Quang Phan; Minchen Chien; David B Weir; Ruchi Choksi; Gabriella De Vita; Daniela Frezzetti; Hans-Ingo Trompeter; Veit Hornung; Grace Teng; Gunther Hartmann; Miklos Palkovits; Roberto Di Lauro; Peter Wernet; Giuseppe Macino; Charles E Rogler; James W Nagle; Jingyue Ju; F Nina Papavasiliou; Thomas Benzing; Peter Lichter; Wayne Tam; Michael J Brownstein; Andreas Bosio; Arndt Borkhardt; James J Russo; Chris Sander; Mihaela Zavolan; Thomas Tuschl Journal: Cell Date: 2007-06-29 Impact factor: 41.582
Authors: Peter Androvic; Lukas Valihrach; Julie Elling; Robert Sjoback; Mikael Kubista Journal: Nucleic Acids Res Date: 2017-09-06 Impact factor: 16.971
Authors: Bruno M D C Godinho; Emily G Knox; Samuel Hildebrand; James W Gilbert; Dimas Echeverria; Zachary Kennedy; Reka A Haraszti; Chantal M Ferguson; Andrew H Coles; Annabelle Biscans; Jillian Caiazzi; Julia F Alterman; Matthew R Hassler; Anastasia Khvorova Journal: Mol Ther Nucleic Acids Date: 2022-06-13 Impact factor: 10.183
Authors: Petra Bencurova; Jiri Baloun; Jakub Hynst; Jan Oppelt; Hana Kubova; Sarka Pospisilova; Milan Brazdil Journal: Sci Rep Date: 2021-05-06 Impact factor: 4.379